{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:53:06Z","timestamp":1761598386462,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk factors do not take the tumor immune microenvironment into account. Consideration of the Immunoscore, which measures the host immune response at the tumor site, may assist clinicians in reducing adjuvant chemotherapy use in patients who are unlikely to benefit from it. This study sought to determine the potential clinical utility of the Immunoscore, via its effect on medical oncologists\u2019 recommendations for management of patients with stage II colon cancer. Methods: De-identified vignettes of 10 patients with stage II colon cancer were presented to 25 practicing medical oncologists. Each participant completed surveys indicating recommendations for adjuvant chemotherapy and surveillance strategies. An educational session was subsequently conducted, and the same patient profiles were re-presented but included immunoscore results. Participants were again asked to provide their recommendations. A participant was counted as influenced if their responses were altered after immunoscore test results were provided. Results: All but one participant (96%) altered a management recommendation for \u22651 case. For individual cases, a mean of 55% (range, 40\u201380%) of participants altered their recommendations for adjuvant chemotherapy and\/or surveillance. For the immunoscore-high cases (low-risk of recurrence), recommendations for adjuvant chemotherapy use decreased from 60% to 31%. Conclusions: These results indicate a willingness by oncologists to integrate immunoscore information into clinical practice recommendations. Incorporation of immunoscore data resulted in the reduction of nonvalue care in the simulated population. Confirmation in prospective studies is planned.<\/jats:p>","DOI":"10.3390\/cancers13215467","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:47:38Z","timestamp":1635767258000},"page":"5467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey"],"prefix":"10.3390","volume":"13","author":[{"given":"Anup","family":"Kasi","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, PA 19111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham M.","family":"Poage","sequence":"additional","affiliation":[{"name":"HalioDx Inc., Richmond, VA 23219, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Catteau","sequence":"additional","affiliation":[{"name":"HalioDx SAS, 13288 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[{"name":"Methodology and Quality of Life in Oncology Unit, Besan\u00e7on Hospital, 25000 Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"George","sequence":"additional","affiliation":[{"name":"Paltown Development Foundation, Crownsville, MD 21032, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Barzi","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Therapeutics Research, Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argiles","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(1999). Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 17, 1356\u20131363.","DOI":"10.1200\/JCO.1999.17.5.1356"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.21037\/jgo.2019.06.03","article-title":"Making sense of adjuvant chemotherapy in colorectal cancer","volume":"10","author":"Chan","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JOP.2016.017210","article-title":"Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma","volume":"13","author":"Kannarkatt","year":"2017","journal-title":"J. Oncol. Pr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0035-1564430","article-title":"Chemotherapy for Stage II Colon Cancer","volume":"28","author":"Varghese","year":"2015","journal-title":"Clin. Colon. Rectal. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study","volume":"370","author":"Gray","year":"2007","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1200\/JCO.2004.03.087","article-title":"Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care\u2019s gastrointestinal cancer disease site group","volume":"22","author":"Figueredo","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/ijc.32629","article-title":"Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data","volume":"146","author":"Jongeneel","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","article-title":"Adjuvant chemotherapy for stage II colon cancer with poor prognostic features","volume":"29","author":"Greenblatt","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2002.11.084","article-title":"Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer","volume":"20","author":"Schrag","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","article-title":"Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial","volume":"30","author":"Tournigand","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Boni","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Vernerey","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COC.0000000000000684","article-title":"Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis","volume":"43","author":"Jiao","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.2004.05.063","article-title":"American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer","volume":"22","author":"Benson","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): Final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andre","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.20.01330","article-title":"Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer","volume":"39","author":"Iveson","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: A prognostic and accuracy study","volume":"391","author":"Pages","year":"2018","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Galon, J., Hermitte, F., Mlecnik, B., Marliot, F., Bifulco, C.B., Lugli, A., Nagtegaal, I.D., Hartmann, A., Eynde, M.V.D., and Roehrl, M.H.A. (2019, January 10\u201317). Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. Proceedings of the ASCO Gastrointestinal Cancers Symposium 2019, San Francisco, CA, USA.","DOI":"10.1200\/JCO.2019.37.4_suppl.487"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2020.38.15_suppl.4105","article-title":"Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients","volume":"38","author":"Galon","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","year":"2001","journal-title":"Stat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1245\/s10434-018-6484-8","article-title":"High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal","volume":"25","author":"Babcock","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaoncol.2021.0177","article-title":"Tumor-Infiltrating Lymphocytes for Prognostic Stratification in Nonmetastatic Colon Cancer-Are We There Yet?","volume":"7","author":"Sinicrope","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1245\/s10434-014-3631-8","article-title":"Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: Analysis of SEER-medicare data","volume":"21","author":"Weiss","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1200\/JCO.2019.37.15_suppl.6648","article-title":"Total Cost of Care for Patients (pts) with Stage II Colon Cancer (CC-II): A SEER-Medicare Analysis","volume":"37","author":"Barzi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","article-title":"The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures","volume":"39","author":"Galon","year":"2013","journal-title":"Immunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.19.03205","article-title":"Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer","volume":"38","author":"Mlecnik","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.annonc.2020.03.310","article-title":"Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study","volume":"31","author":"Taieb","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"pkaa023","DOI":"10.1093\/jncics\/pkaa023","article-title":"Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer","volume":"4","author":"Sinicrope","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Naidoo, M., Gibbs, P., and Tie, J. (2021). ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. Cancers, 13.","DOI":"10.3390\/cancers13020346"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"346ra392","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","article-title":"Systematic review of microsatellite instability and colorectal cancer prognosis","volume":"23","author":"Popat","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.18.02059","article-title":"Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial","volume":"37","author":"Ueno","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/PAS.0000000000001409","article-title":"Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients","volume":"44","author":"Fuchs","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00384-021-03896-9","article-title":"Adjuvant chemotherapy in stage II and III colon cancer: The role of the \u201cbudding and TILs-(tumor-infiltrating lymphocytes) combination\u201d as tumor-host antagonists","volume":"36","author":"Melcher","year":"2021","journal-title":"Int. J. Colorectal Dis."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:38Z","timestamp":1760167418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215467"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215467","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,10,30]]}}}